1. Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China. 2. Stomatological college of Nanjing Medical University, Nanjing, Jiangsu, China. 3. Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. 4. Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. 5. Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University,Nanjing, Jiangsu, China. *Indicates first authors.
✉ Corresponding authors: Dr. Yongxiang Xia, E-mail: yx_xiaedu.cn; Dr. Weiwei Tang, E-mail: 1243773473twwwcom.
Citation:
Cao H, Huang T, Dai M, Kong X, Liu H, Zheng Z, Sun G, Sun G, Rong D, Jin Z, Tang W, Xia Y. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. Int J Biol Sci 2022; 18(14):5369-5390. doi:10.7150/ijbs.73949. https://www.ijbs.com/v18p5369.htm
The incidence of cholangiocarcinoma (CCA) has been increasing over the past few years. Although there are surgery, chemotherapy and other conventional treatment methods, the effect is not as expected. At present, immunotherapy has become the research frontier of cancer treatment, and CCA tumor microenvironment (TME) is becoming a hot exploration direction of immunobiology. TME can affect tumor progression through changes in metabolism, secretion and immunity. Accordingly, understanding the role played by immune cells and stromal cells in TME is important for the study of CCA immunotherapy. This review will discuss the interactions between immune cells (including CD8+ T cells, CD4+ T cells, macrophages, natural killer cells, dendritic cells, myeloid suppressor cells, mast cells, and neutrophils) and stromal cells (including cancer-associated fibroblasts, endothelial cells) in the TME of CCA. In addition, we will also discuss current research results on TME of CCA and recent advances in immunotherapy.
Cao, H., Huang, T., Dai, M., Kong, X., Liu, H., Zheng, Z., Sun, G., Sun, G., Rong, D., Jin, Z., Tang, W., Xia, Y. (2022). Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. International Journal of Biological Sciences, 18(14), 5369-5390. https://doi.org/10.7150/ijbs.73949.
ACS
Cao, H.; Huang, T.; Dai, M.; Kong, X.; Liu, H.; Zheng, Z.; Sun, G.; Sun, G.; Rong, D.; Jin, Z.; Tang, W.; Xia, Y. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. Int. J. Biol. Sci. 2022, 18 (14), 5369-5390. DOI: 10.7150/ijbs.73949.
NLM
Cao H, Huang T, Dai M, Kong X, Liu H, Zheng Z, Sun G, Sun G, Rong D, Jin Z, Tang W, Xia Y. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. Int J Biol Sci 2022; 18(14):5369-5390. doi:10.7150/ijbs.73949. https://www.ijbs.com/v18p5369.htm
CSE
Cao H, Huang T, Dai M, Kong X, Liu H, Zheng Z, Sun G, Sun G, Rong D, Jin Z, Tang W, Xia Y. 2022. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies. Int J Biol Sci. 18(14):5369-5390.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.